Menu
An innovative and commercially orientated biotechnology and pharmaceutical business at the cutting edge of stem cell research.
The business now comprises a group of companies. It’s always been managed with positive capital, and a view to a preferred public markets exit for investors. In anticipation of this up to £10m secondaries are available.
The business benefitted from the very early introduction of capital by Ruffena which was augmented by money from fund-raising platforms.
Having successfully raised the required investment, the business then struck a transformative deal with a major Japanese pharma company and has gone on to spin out companies with value benefit for investors.
An innovative and commercially orientated biotechnology and pharmaceutical business at the cutting edge of stem cell research.
The business now comprises a group of companies. It’s always been managed with positive capital, and a view to a preferred public markets exit for investors. In anticipation of this up to £10m secondaries are available.
The business benefitted from the very early introduction of capital by Ruffena which was augmented by money from fund-raising platforms.
Having successfully raised the required investment, the business then struck a transformative deal with a major Japanese pharma company and has gone on to spin out companies with value benefit for investors.